These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6661512)

  • 1. Pharmacokinetics of glucuronidation of propranolol following oral administration in humans.
    Midha KK; Roscoe RM; Wilson TW; Cooper JK; Loo JC; Ho-Ngoc A; McGilveray IJ
    Biopharm Drug Dispos; 1983; 4(4):331-8. PubMed ID: 6661512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presystemic and systemic glucuronidation of propranolol.
    Walle T; Fagan TC; Conradi EC; Walle UK; Gaffney TE
    Clin Pharmacol Ther; 1979 Aug; 26(2):167-72. PubMed ID: 455886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relative bioavailability of a commercial propranolol hydrochloride tablet in man.
    Roscoe R; Cooper J; Wilson TW; Joshi NN; Midha KK
    Biopharm Drug Dispos; 1982; 3(2):105-14. PubMed ID: 7104460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereoselective disposition and glucuronidation of propranolol in humans.
    Silber B; Holford NH; Riegelman S
    J Pharm Sci; 1982 Jun; 71(6):699-704. PubMed ID: 7097538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-dependent disposition of oral propranolol in normal subjects.
    Mackichan JJ; Pyszczynski DR; Jusko WJ
    Biopharm Drug Dispos; 1980; 1(4):159-66. PubMed ID: 7448344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereoselective oral bioavailability of (+/-)-propranolol in the dog. A GC-MS study using a stable isotope technique.
    Walle T; Walle UK
    Res Commun Chem Pathol Pharmacol; 1979 Mar; 23(3):453-64. PubMed ID: 461970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereoselective increase in propranolol bioavailability during chronic dosing in the dog.
    Bai SA; Wilson MJ; Walle UK; Walle T
    J Pharmacol Exp Ther; 1983 Nov; 227(2):360-4. PubMed ID: 6631718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial metabolic clearances as determinants of the oral bioavailability of propranolol.
    Walle T; Walle UK; Olanoff LS; Conradi EC
    Br J Clin Pharmacol; 1986 Sep; 22(3):317-23. PubMed ID: 3768243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability of propranolol in the dog.
    Tse FL; Sanders TM; Reo JP
    Arch Int Pharmacodyn Ther; 1980 Dec; 248(2):180-9. PubMed ID: 7224706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct measurement of propranolol bioavailability during accumulation to steady-state.
    Wood AJ; Carr K; Vestal RE; Belcher S; Wilkinson GR; Shand DG
    Br J Clin Pharmacol; 1978 Oct; 6(4):345-50. PubMed ID: 698031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No stereoselective first-pass hepatic extraction of propranolol.
    Jackman GP; McLean AJ; Jennings GL; Bobik A
    Clin Pharmacol Ther; 1981 Sep; 30(3):291-6. PubMed ID: 7273593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma concentrations and bioavailability of propranolol by oral, rectal, and intravenous administration in man.
    Cid E; Mella F; Lucchini L; Cárcamo M; Monasterio J
    Biopharm Drug Dispos; 1986; 7(6):559-66. PubMed ID: 3828485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between plasma propranolol concentration and dose in young, healthy volunteers.
    Dey M; Brisson J; Davis G; Enever R; Pray K; Zaim B; Dvornik D
    Biopharm Drug Dispos; 1986; 7(2):103-11. PubMed ID: 3708118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability of propranolol hydrochloride tablet formulations: application of multiple dose crossover studies.
    Eldon MA; Kinkel AW; Daniel JE; Latts JR
    Biopharm Drug Dispos; 1989; 10(1):69-76. PubMed ID: 2923962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereochemical composition of propranolol metabolites in the dog using stable isotope-labeled pseudoracemates.
    Walle T; Wilson MJ; Walle UK; Bai SA
    Drug Metab Dispos; 1983; 11(6):544-9. PubMed ID: 6140137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereospecific assay for (-)- and (+)-propranolol in human and dog plasma.
    Silber B; Riegelman S
    J Pharmacol Exp Ther; 1980 Dec; 215(3):643-8. PubMed ID: 7441523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of ageing on the hepatic clearance of propranolol.
    Castleden CM; George CF
    Br J Clin Pharmacol; 1979 Jan; 7(1):49-54. PubMed ID: 760742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of propranolol: a review.
    Shand DG
    Postgrad Med J; 1976; 52 Suppl 4():22-25. PubMed ID: 787953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased absorption as a possible cause for the lower bioavailability of a sustained-release propranolol.
    Takahashi H; Ogata H; Warabioka R; Kashiwada K; Ohira M; Someya K
    J Pharm Sci; 1990 Mar; 79(3):212-5. PubMed ID: 2338628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism by which hydralazine increases propranolol bioavailability.
    Schneck DW; Vary JE
    Clin Pharmacol Ther; 1984 Apr; 35(4):447-53. PubMed ID: 6705442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.